Matsunaga Tomoyuki, Miyata Hiroshi, Sugimura Keijiro, Motoori Masaaki, Asukai Kei, Yanagimoto Yoshitomo, Yamamoto Kazuyoshi, Akita Hirofumi, Nishimura Junichi, Wada Hiroshi, Takahashi Hidenori, Yasui Masayoshi, Omori Takeshi, Ohue Masayuki, Fujiwara Yoshiyuki, Yano Masahiko
Department of Digestive Surgery, Osaka International Cancer Institute, Osaka 541-8567, Japan.
Division of Surgical Oncology, Department of Surgery, School of Medicine, Tottori University Faculty of Medicine, Yonago 683-8503, Japan.
Yonago Acta Med. 2019 Dec 13;63(1):8-19. doi: 10.33160/yam.2020.02.002. eCollection 2020 Feb.
The prognostic value of combination of C-reactive protein and prealbumin (CRP/PAlb) in esophageal cancer remains unclear.
We enrolled 167 esophageal cancer patients who underwent curative esophagectomy. Univariate and multivariate analyses were performed to determine the prognostic significance of various markers, including CRP-to-albumin (CRP/Alb) ratio, modified Glasgow prognostic score, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and prognostic nutritional index.
Receiver operating characteristic analysis revealed the optimal cut-off value of each inflammatory factor, and CRP/PAlb ratio had the greatest discriminative power in predicting recurrence-free survival (RFS) among the examined measures (AUC 0.668). The 5-year overall survival and RFS rates were significantly lower in patients with high CRP/PAlb ratio than in those with low CRP/PAlb ratio ( < 0.001, = 0.001, respectively). In the univariate analysis, RFS was significantly worse in patients with low BMI, T2 or deeper tumor invasion, positive lymph node metastasis, positive venous invasion, high CRP/PAlb ratio, high CRP/Alb ratio, high NLR, and high LMR. Multivariate analysis revealed that CRP/PAlb, but not CRP/Alb, was an independent prognostic factor along with lymph node metastasis.
CRP/PAlb ratio was useful for predicting the prognosis of esophageal cancer patients.
C反应蛋白与前白蛋白联合检测(CRP/PAlb)在食管癌中的预后价值尚不清楚。
我们纳入了167例行根治性食管切除术的食管癌患者。进行单因素和多因素分析以确定各种标志物的预后意义,包括CRP与白蛋白比值(CRP/Alb)、改良格拉斯哥预后评分、中性粒细胞与淋巴细胞比值(NLR)、血小板与淋巴细胞比值(PLR)以及预后营养指数。
受试者工作特征分析揭示了每种炎症因子的最佳截断值,并且在检测的指标中,CRP/PAlb比值在预测无复发生存期(RFS)方面具有最大的判别能力(AUC 0.668)。高CRP/PAlb比值患者的5年总生存率和RFS率显著低于低CRP/PAlb比值患者(分别为<0.001,=0.001)。在单因素分析中,低BMI、T2期或更深的肿瘤浸润、阳性淋巴结转移、阳性静脉浸润、高CRP/PAlb比值、高CRP/Alb比值、高NLR和高LMR的患者RFS显著更差。多因素分析显示,CRP/PAlb而非CRP/Alb与淋巴结转移一样是独立的预后因素。
CRP/PAlb比值有助于预测食管癌患者的预后。